Home › Acute Myeloid Leukemia › Kansas › Kansas City
Acute Myeloid Leukemia clinical trials in Kansas City, KS
12 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- University of Kansas Cancer Center, Kansas City
Ivosidenib as Post-HSCT Maintenance for AML
RecruitingPhase 2
- Kansas University Medical Center, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Veteran Administration Eastern Kansas Healthcare, Leavenworth · 21 mi away
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Kansas Cancer Center, Kansas City
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Kansas Cancer Center, Kansas City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Kansas Cancer Center, Kansas City
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Kansas Cancer Center, Kansas City
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- US-Kansas City KS-KUMC, Kansas City
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
RecruitingPhase 1
- University of Kansas Cancer Center, Kansas City
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- The University of Kansas Cancer Center, Kansas City
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RecruitingPhase 1
- University of Kansas Medical Center Research Institute, Inc., Kansas City
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RecruitingPhase 1
- KU Cancer Center, Kansas City
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Other studies in Kansas City
- Cardiovascular Disease14 studies
- Heart Failure13 studies
- Obesity13 studies
- Interstitial Lung Diseases13 studies
- Cystic Fibrosis13 studies
- Breast Cancer12 studies
- Bladder Cancer12 studies
- Prostate Cancer12 studies
- Non-Small Cell Lung Cancer11 studies
- Lung Cancer11 studies
- COPD9 studies
- Asthma8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.